- Home
- SLQT vs ABOS Comparison
SLQT vs ABOS Comparison
Compare SLQT & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLQT | ABOS |
|---|---|---|
| Founded | 1999 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.6M | 155.7M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SLQT | ABOS |
|---|---|---|
| Price | $0.61 | $2.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $2.88 | ★ $7.75 |
| AVG Volume (30 Days) | ★ 1.4M | 452.4K |
| Earning Date | 02-05-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.00 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $1,526,594,000.00 | N/A |
| Revenue This Year | $11.42 | N/A |
| Revenue Next Year | $7.76 | N/A |
| P/E Ratio | $61.98 | ★ N/A |
| Revenue Growth | ★ 15.50 | N/A |
| 52 Week Low | $0.60 | $0.86 |
| 52 Week High | $3.97 | $3.60 |
Technical Indicators
Market Signals| Indicator | SLQT | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 24.79 | 40.31 |
| Support Level | N/A | $1.21 |
| Resistance Level | $0.94 | $3.05 |
| Average True Range (ATR) | 0.05 | 0.28 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 6.04 | 0.00 |
Price Performance
Historical ComparisonAbout SLQT SelectQuote Inc.
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.